The present invention relates to compounds of the general formula (1), wherein R1 3,6-dihydro-2H-pyran-4-yl, 5,6-dihydro-4H-pyran-3-yl, t,6-dihydro-4H-pyran-2-yl, tetrahydropyran-2,3 or 4-yl, cyclohex-1-enyl, cyclohexyl or is 1,2,3,6-tetrahydro-pyridin-4yl or piperidin-4-yl, which are optionally substituted C(O)CH3in the 1-position of the N-atom; R2 is lower alkyl, piperidin-1yl, optionally substituted by hydroxy, or is phenyl, optionally substituted by (CH2)n-N(R')-C(O)-(CH2)n-NR'2,-(CH2)n-halogen, lower alkyl or (CH2)n-O-lower alkyl, or is morpholinyl or is pyridinyl, which is optionally substituted by halogen, -N(R')-(CH2)n-O-lower alkyl, lower alkyl, lower alkoxy, morpholinyl or (CH2)n-pyrrolidinyl; n is 0, 1 or 2; R' is hydrogen or lower alkyl, and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compounds of general formula I are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A2A-receptor and they may be used in the treatment of diseases, related to this receptor.